DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,104 filers reported holding DANAHER CORPORATION in Q4 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $749,160 | +7.9% | 3,000 | 0.0% | 0.36% | -9.9% |
| Q4 2023 | $694,020 | -29.8% | 3,000 | -33.3% | 0.40% | -36.5% |
| Q3 2023 | $988,560 | -8.5% | 4,500 | 0.0% | 0.64% | -8.3% |
| Q2 2023 | $1,080,000 | -42.9% | 4,500 | -40.0% | 0.70% | -46.6% |
| Q1 2023 | $1,890,300 | -5.0% | 7,500 | 0.0% | 1.30% | -21.6% |
| Q4 2022 | $1,990,650 | -99.9% | 7,500 | 0.0% | 1.66% | +0.2% |
| Q3 2022 | $1,935,000,000 | -22.1% | 7,500 | -11.8% | 1.66% | +9.2% |
| Q2 2022 | $2,484,550,000 | 0.0% | 8,500 | 0.0% | 1.52% | -0.6% |
| Q1 2022 | $2,484,550,000 | -55.6% | 8,500 | -50.0% | 1.53% | +1.6% |
| Q4 2021 | $5,593,000,000 | +93.4% | 17,000 | +78.9% | 1.50% | -3.1% |
| Q3 2021 | $2,891,800,000 | +10.7% | 9,500 | -2.6% | 1.55% | +13.6% |
| Q2 2021 | $2,613,000,000 | +118997.5% | 9,750 | 0.0% | 1.37% | -0.2% |
| Q1 2021 | $2,194,000 | -8.0% | 9,750 | -9.3% | 1.37% | -4.1% |
| Q4 2020 | $2,386,000 | +0.9% | 10,750 | -2.3% | 1.43% | -6.2% |
| Q3 2020 | $2,365,000 | – | 11,000 | – | 1.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
| WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
| Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
| Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
| CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
| Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
| Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
| Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
| Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
| Third Point | 3,570,000 | $494,124,000 | 7.88% |